股票代码：605116 股票简称：奥锐特 关于奥锐特药业股份有限公司 向不特定对象发行可转换公司债券 申请文件审核问询函的回复报告 保荐机构（主承销商） 二〇二三年八月 上海证券交易所： 贵所于 2023 年 7 月 17 日出具的《关于奥锐特药业股份有限公司向不特定 对象发行可转换公司债券申请文件的审核问询函》（上证上审（再融资）〔2023〕 491 号）（下称"审核问询函"）已收悉。奥锐特药业股份有限公司（下称"奥 锐特"、"发行人"或"公司"）与海通证券股份有限公司（下称"保荐机构"）、 国浩律师（杭州）事务所（下称"发行人律师"）、天健会计师事务所（特殊 普通合伙）（下称"申报会计师"）等相关方，本着勤勉尽责、诚实守信的原 则，就审核问询函所提问题逐条进行了认真讨论、核查和落实，现回复如下， 请予审核。 如无特别说明，本回复中的简称与募集说明书中简称具有相同含义。 | 格式 | 说明 | | --- | --- | | 黑体（不加粗） | 审核问询函所列问题 | | 宋体（不加粗） | 对审核问询函所列问题的回复，或对募集说明书的引用 | | 楷体（加粗） | 对募集说明书等申请文件补充披露或修订的内 ...

关于奥锐特药业股份有限公司 向不特定对象发行可转换公司债券 之 发行保荐书 海通证券股份有限公司 保荐机构（主承销商） （上海市广东路 689 号） 二〇二三年八月 声 明 本保荐机构及保荐代表人根据《中华人民共和国公司法》（以下简称《公司 法》）、《中华人民共和国证券法》（以下简称《证券法》）、《证券发行上市 保荐业务管理办法》（以下简称《保荐管理办法》）、《上市公司证券发行注册 管理办法》（以下简称《注册管理办法》）、《上海证券交易所股票上市规则》 （以下简称《上市规则》）等有关法律、行政法规和中国证券监督管理委员会（以 下简称中国证监会）、上海证券交易所的规定，诚实守信，勤勉尽责，严格按照 依法制订的业务规则、行业执业规范和道德准则出具本发行保荐书，并保证所出 具文件的真实性、准确性和完整性。 如无特殊说明，本发行保荐书中的简称或名词释义与《奥锐特药业股份有限 公司向不特定对象发行可转换公司债券之募集说明书》一致。 3-1-1 | 声 | 明 1 | | --- | --- | | 第一节 | 本次证券发行基本情况 3 | | | 一、本次证券发行保荐机构名称 3 | | | 二、保荐机构指定保荐代表人 ...

海通证券股份有限公司 关于奥锐特药业股份有限公司 向不特定对象发行可转换公司债券 之 如无特殊说明，本上市保荐书中的简称或名词释义与《奥锐特药业股份有限 公司向不特定对象发行可转换公司债券之募集说明书》一致。 3-2-1 | | | | 声 | 明 1 | | --- | --- | | 目 | 录 2 | | | 一、发行人基本情况 3 | | | 二、 发行人本次发行情况 13 | | | 三、 本次证券发行上市的项目保荐代表人、协办人及项目组其他成员保荐 | | | 业务执业情况及承诺事项 23 | | | 四、保荐机构是否存在可能影响公正履行保荐职责情形的说明 24 | | | 五、保荐机构承诺事项 24 | | | 六、本次证券发行上市履行的决策程序 25 | | | 七、保荐机构关于符合国家产业政策和板块定位的核查情况 26 | | | 八、本次向不特定对象发行可转换公司债券符合规定 27 | | | 九、保荐机构对发行人持续督导工作的安排 36 | | | 十、保荐机构和保荐代表人联系方式 36 | | | 十一、保荐机构认为应当说明的其他事项 37 | | | 十二、保荐机构对本次股票上市的推 ...

目 录 | 一、关于融资规模以及效益测算………………………………第 | 1—58 | 页 | | --- | --- | --- | | 二、关于业绩及经营情况………………………………………第 | 58—109 | 页 | | 三、关于财务性投资……………………………………………第 | 110—117 | 页 | 关于奥锐特药业股份有限公司 向不特定对象发行可转换公司债券申请文件的审核 问询函中有关财务事项的说明 天健函〔2023〕1151 号 上海证券交易所： 程，建筑面积、设备购置数量的确定依据及合理性，与新增产能的匹配关系， 建筑单价、设备单价以及安装费与公司已投产项目及同行业公司可比项目是否 存在明显差异；（2）结合本次募投项目非资本性支出情况、说明实质上用于补 流的规模及其合理性，相关比例是否超过本次募集资金总额的 30%，是否存在置 换董事会前投入的情形；（3）结合公司现有资金余额、用途、缺口和现金流入 金额，说明本次融资规模的合理性；（4）效益预测中产品价格、成本费用等关 键指标的具体预测过程及依据，与公司现有水平及同行业可比公司的对比情况， 相关预测是否审慎、合理。 由海通证券股份有限公司转来 ...

国浩律师（杭州）事务所 关 于 奥锐特药业股份有限公司 向不特定对象发行可转换公司债券 之 补充法律意见书（一） 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二〇二三年八月 补充法律意见书（一） 国浩律师（杭州）事务所 国浩律师（杭州）事务所 关 于 奥锐特药业股份有限公司 向不特定对象发行可转换公司债券 之 补充法律意见书（一） 致：奥锐特药业股份有限公司 国浩律师（杭州）事务所（以下简称"本所"）作为奥锐特药业股份有限公 司聘任的，为其向不特定对象发行可转换公司债券提供法律服务的发行人律师， 于 ...

证券代码：605116 证券简称：奥锐特 公告编号：2023-039 特此公告。 奥锐特药业股份有限公司 奥锐特药业股份有限公司董事会 关于向不特定对象发行可转换公司债券申请文件的 审核问询函回复的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 奥锐特药业股份有限公司（以下简称"公司"）于 2023 年 7 月 17 日收到上 海证券交易所（以下简称"上交所"）出具的《关于奥锐特药业股份有限公司向 不特定对象发行可转换公司债券申请文件的审核问询函》（上证上审（再融资） 〔2023〕491 号）（以下简称"问询函"）。上交所审核机构对公司提交的向不特 定对象发行可转换公司债券申请文件进行了审核，并形成了首轮问询问题。 公司收到审核问询函后，会同相关中介机构结合公司情况就审核问询函中提 出的问题进行了认真研究和逐项落实，现根据要求将审核问询函回复进行公开披 露，具体内容详见公司同日在上交所网站（www.sse.com.cn）披露的《关于奥锐 特药业股份有限公司向不特定对象发行可转换公司债券申请文件的审核问询函 的回复》 ...

股票代码：605116 股票简称：奥锐特 奥锐特药业股份有限公司 Aurisco Pharmaceutical Co.,Ltd. （住所：浙江省天台县八都工业园区） 向不特定对象发行可转换公司债券 募集说明书 保荐机构（主承销商） （上海市广东路 689 号） 二〇二三年八月 1-1-1 奥锐特药业股份有限公司 向不特定对象发行可转换公司债券募集说明书 声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的投资风险。 1-1-2 奥锐特药业股份有限公司 向不特定对象发行可转换公司债券募集说明书 重大事项提示 投资者在评价公司本次发行的可转换公司债券时，应特别关注下列重大事 项： 一、公司本次发行的可转换公司债券的信用评级 本次 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥302,135,926.13, representing a year-on-year increase of 38.07%[6] - The net profit attributable to shareholders of the listed company was ¥45,877,847.97, reflecting a growth of 12.30% compared to the same period last year[6] - Basic earnings per share for the period were ¥0.11, which is a 10.00% increase from the previous year[6] - Total revenue for Q1 2023 reached ¥302,135,926.13, a 38.0% increase from ¥218,833,057.33 in Q1 2022[46] - Operating profit for Q1 2023 was ¥58,973,162.21, compared to ¥53,425,178.89 in Q1 2022, reflecting a 10.0% increase[47] - Net profit for Q1 2023 was ¥45,710,870.38, an increase of 12.0% from ¥40,535,906.17 in Q1 2022[47] - The total comprehensive income attributable to the parent company owners rose to ¥45,666,820.85, compared to ¥40,575,787.80, indicating an increase of about 12.5%[1] - The total comprehensive income for the period reached ¥45,499,843.26, up from ¥40,259,023.99, marking an increase of about 13.5%[1] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥79,859,097.31, showing a significant increase of 214.67% year-on-year[6] - The total cash inflow from operating activities amounted to ¥322,269,254.53, up from ¥256,057,499.13 in Q1 2022[9] - Cash outflow from operating activities was ¥242,410,157.22, compared to ¥230,678,487.89 in the same quarter last year[9] - The significant increase in cash flow is attributed to enhanced sales performance during the reporting period[2] - The net cash flow from operating activities surged by 214.67%, mainly due to an increase in cash received from sales of goods[2] - The company's cash and cash equivalents at the end of the first quarter of 2023 were approximately 382.24 million, compared to 417.75 million at the end of 2022, indicating a decrease of about 8.5%[37] - The net increase in cash and cash equivalents for the first quarter of 2023 was approximately 43.69 million, contrasting with a decrease of about 22.59 million in the same period of the previous year[37] Assets and Liabilities - As of March 31, 2023, the company's total current assets amounted to approximately 1.14 billion, an increase from 1.09 billion as of December 31, 2022, representing a growth of about 5.5%[31] - The company's total assets as of March 31, 2023, were approximately 2.11 billion, reflecting a year-over-year increase of 3.77% from 2.03 billion[38] - Total liabilities rose to ¥368,497,742.33, up from ¥348,684,087.93, indicating a 5.0% increase[46] - The company's total equity attributable to shareholders was approximately 1.73 billion, an increase of 3.4% from 1.68 billion at the end of the previous year[38] - The company's equity attributable to shareholders increased to ¥1,733,075,449.62 from ¥1,676,167,948.81, a growth of 3.4%[46] Operational Highlights - The company received government subsidies amounting to ¥2,865,008.34, which are closely related to its normal business operations[24] - The company reported a non-operating loss of ¥39,363.83 from the disposal of non-current assets[24] - The cash received from sales of goods and services was ¥283,108,059.34, compared to ¥220,963,775.27 in Q1 2022[9] - The company's inventory as of March 31, 2023, was approximately 440.81 million, slightly down from 444.94 million at the end of 2022, showing a decrease of about 0.5%[31] - The company had a total of 6,825 common shareholders at the end of the reporting period, with the largest shareholder holding 37.81% of the shares[40] Research and Development - Research and development expenses for Q1 2023 amounted to ¥25,717,254.75, a decrease of 20.0% from ¥32,181,663.57 in Q1 2022[47] - The company did not disclose any new product developments or market expansion strategies in the report[30] Shareholder Information - The net loss attributable to minority shareholders decreased to -¥166,977.59 from -¥316,763.81, showing an improvement of approximately 47.4%[1] - The company did not report any audit opinion type applicable for this period[3]

证券代码：605116 证券简称：奥锐特 公告编号：2023-024 奥锐特药业股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.s seinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 04 月 20 日(星期四) 至 04 月 26 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@aurisco. com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 奥锐特药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 15 日发布 公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营 成果、财务状况，公司计划于 2023 年 04 月 27 日 下午 14:00-15:00 举行 2022 年度业绩说明会，就投资者关心的问题进行交流 ...

Financial Performance - In 2022, the company achieved operating revenue of CNY 1.008 billion, a year-on-year increase of 25.48%[36] - The net profit attributable to shareholders was CNY 211 million, reflecting a growth of 25.00% compared to the previous year[36] - The net profit attributable to the parent company after deducting non-recurring gains and losses was CNY 207 million, up 26.56% year-on-year[36] - The company's main business revenue for the current period is CNY 1,000,848,370.61, representing a year-on-year increase of 25.03% from CNY 800,459,806.62[80] - The total operating costs for the current period amount to CNY 487,676,482.77, which is a 19.34% increase compared to CNY 408,644,195.42 in the previous year[81] - The gross profit margin for the main business increased by 2.38 percentage points to 51.50% compared to the previous year[81] - The company achieved a total operating revenue of 1,008,076,473.51 RMB, representing a year-on-year increase of 25.48%[101] - The gross profit margin improved, with operating costs rising to 487,676,482.77 RMB, an increase of 19.34% compared to the previous year[101] - The company reported a total of 71,644,825.31 RMB in trade product revenue, which decreased by 11.30% compared to the previous year[89] - The revenue from trade products remained stable at ¥88,559,794.94, showing a slight decrease of 6.62%[105] Research and Development - The company invested CNY 117.26 million in R&D during the reporting period, representing a year-on-year increase of 69.09%[47] - There are currently 30 products in the R&D stage, including chemical APIs, peptide APIs, and oligonucleotide APIs[47] - The company has formed a strong R&D capability with six engineering technology innovation platforms, focusing on high-end pharmaceutical intermediates and APIs[57] - The company is developing multiple oligonucleotide API products to better serve clients and support their product launches[47] - The company has established long-term cooperative relationships with several domestic universities and research institutes to enhance its technological capabilities[57] - The company operates six R&D centers located in various regions, focusing on small molecule drugs, peptide drugs, and innovative drug development[125] - The company's R&D investment reached RMB 117.26 million, accounting for 11.63% of revenue, with a year-on-year growth of 69.09%[150] - R&D investment amounted to 6,882.46 million RMB, representing 12.08% of operating revenue and 5.52% of net assets[170] - The average R&D investment in the industry was 27,079.03 million RMB, with the company's R&D investment accounting for 11.63% of operating revenue and 7.00% of net assets[170] Product Development and Sales - The overall sales of cardiovascular products increased by 31.19% year-on-year, driven by the commercialization of key raw materials[66] - The sales of anti-tumor products surged by 248.42%, primarily due to the growth in sales of Abiraterone acetate and increased demand from both existing and new customers[66] - The company produced 22,444.93 kg of cardiovascular products, with sales increasing by 58.08% year-on-year[108] - The revenue from the oncology segment surged by 248.42% year-over-year, reaching 14,066.64 million RMB[123] - The female health product segment achieved revenue of CNY 194,403,869.14, marking a 17.35% increase due to new customer acquisition[83] - The respiratory system products' revenue remained stable at CNY 151,925,618.98, showing a slight decline of 0.91% year-on-year[83] - The gross margin for the female health segment was 75.03%, with a revenue increase of 17.35% compared to the previous year[123] - The gross margin for the anti-infection segment was 41.83%, with a year-over-year decrease of 5.61% in revenue[123] Market Expansion and Strategy - The company has established a U.S. business development team to accelerate market penetration and custom processing business[66] - The company is actively expanding its export of specialty APIs to meet CDMO business demands and broaden its formulation market[49] - The company has developed a complete sales system for APIs in the Americas, Europe, and Asia, establishing stable long-term partnerships with major pharmaceutical companies[58] - The company plans to expand its marketing network and strengthen relationships with existing customers while penetrating markets in Europe, America, and Asia[167] - The company aims to develop a high-quality technology platform covering six major fields, including respiratory, cardiovascular, and oncology[164] - The company is focusing on enhancing its market competitiveness and increasing the domestic market share in response to international trade risks[168] - The company has established a marketing center in Shanghai to unify product sales and expand market reach through various channels[152] Financial Position and Liabilities - Total assets increased by 18.09% year-on-year, reaching CNY 2.033 billion by the end of 2022[32] - As of the end of 2022, the company's total assets reached 2.033 billion yuan, an increase of 18.09% compared to the beginning of the year[61] - The company's total liabilities amounted to 349 million yuan, reflecting a growth of 63.37% from the start of the year[61] - The total equity attributable to the parent company was 1.676 billion yuan, up 11.28% year-on-year[61] - The company’s total liabilities included 39,984,808.44 RMB in employee compensation payables, reflecting a 32.30% increase due to personnel growth[99] Operational Challenges and Risks - The company faces risks related to environmental compliance, safety production, and potential regulatory changes in the pharmaceutical industry[190][192] - The company's financial expenses were impacted by exchange rate fluctuations, leading to changes in foreign exchange gains[80] - The total cash flow from financing activities was affected by the implementation of equity incentives during the period[80] - The overall increase in sales costs was primarily due to the expansion of sales scale, which necessitated higher expenditure[80] - The company reported a significant increase in cash outflows from financing activities, totaling 109,176,692.10 RMB, which is an increase of 108.01% compared to the previous year[97]